[go: up one dir, main page]

PE20181019A1 - Monohidrato de (s)-lactato de 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1h-pirazol-3-ilamino)pirazin-2-carbonitrilo - Google Patents

Monohidrato de (s)-lactato de 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1h-pirazol-3-ilamino)pirazin-2-carbonitrilo

Info

Publication number
PE20181019A1
PE20181019A1 PE2018000982A PE2018000982A PE20181019A1 PE 20181019 A1 PE20181019 A1 PE 20181019A1 PE 2018000982 A PE2018000982 A PE 2018000982A PE 2018000982 A PE2018000982 A PE 2018000982A PE 20181019 A1 PE20181019 A1 PE 20181019A1
Authority
PE
Peru
Prior art keywords
lactate
monohydrate
aminopropoxi
carbonitrilo
metoxifenil
Prior art date
Application number
PE2018000982A
Other languages
English (en)
Inventor
Alessandra B Ennett-Shepard
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20181019A1 publication Critical patent/PE20181019A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion refiere un compuesto que es monohidrato de (S)-lactato de 5-(5-(2-(3-aminopropoxil)-6-metoxifenil)-1H-pirazol-3-ilamino) pirazina-2-carbonitrilo en forma cristalina. Refiere tambien una composicion farmaceutica que comprende uno o mas portadores, diluyentes o excipientes farmaceuticamente aceptables. La presente invencion es util para el tratamiento del cancer..
PE2018000982A 2015-12-07 2016-12-01 Monohidrato de (s)-lactato de 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1h-pirazol-3-ilamino)pirazin-2-carbonitrilo PE20181019A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562263908P 2015-12-07 2015-12-07

Publications (1)

Publication Number Publication Date
PE20181019A1 true PE20181019A1 (es) 2018-06-26

Family

ID=57570601

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000982A PE20181019A1 (es) 2015-12-07 2016-12-01 Monohidrato de (s)-lactato de 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1h-pirazol-3-ilamino)pirazin-2-carbonitrilo

Country Status (26)

Country Link
US (1) US10189818B2 (es)
EP (1) EP3386975B1 (es)
JP (1) JP6340485B2 (es)
KR (1) KR20180079411A (es)
CN (1) CN108349948B (es)
AR (1) AR106772A1 (es)
AU (1) AU2016367041B2 (es)
BR (1) BR112018008398A2 (es)
CA (1) CA3003914A1 (es)
CL (1) CL2018001432A1 (es)
CO (1) CO2018005676A2 (es)
EA (1) EA201890953A1 (es)
EC (1) ECSP18042905A (es)
ES (1) ES2755740T3 (es)
HK (1) HK1254207B (es)
IL (1) IL258645A (es)
MX (1) MX2018006899A (es)
NZ (1) NZ741739A (es)
PE (1) PE20181019A1 (es)
PH (1) PH12018501213A1 (es)
SG (1) SG11201803713WA (es)
SV (1) SV2018005703A (es)
TN (1) TN2018000125A1 (es)
TW (1) TWI627168B (es)
WO (1) WO2017100071A1 (es)
ZA (1) ZA201802727B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202107932D0 (en) * 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314108B2 (en) * 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
ES2621857T3 (es) * 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1

Also Published As

Publication number Publication date
KR20180079411A (ko) 2018-07-10
ZA201802727B (en) 2019-09-25
CN108349948B (zh) 2021-02-23
TN2018000125A1 (en) 2019-10-04
BR112018008398A2 (pt) 2018-10-23
ES2755740T3 (es) 2020-04-23
SG11201803713WA (en) 2018-06-28
US20180230132A1 (en) 2018-08-16
JP2018501263A (ja) 2018-01-18
CO2018005676A2 (es) 2018-06-12
ECSP18042905A (es) 2018-06-30
CA3003914A1 (en) 2017-06-15
MX2018006899A (es) 2018-09-06
NZ741739A (en) 2019-03-29
AR106772A1 (es) 2018-02-14
CL2018001432A1 (es) 2018-08-31
AU2016367041A1 (en) 2018-05-10
PH12018501213A1 (en) 2019-02-04
SV2018005703A (es) 2018-11-01
IL258645A (en) 2018-06-28
TW201728578A (zh) 2017-08-16
TWI627168B (zh) 2018-06-21
JP6340485B2 (ja) 2018-06-06
EA201890953A1 (ru) 2018-11-30
EP3386975A1 (en) 2018-10-17
EP3386975B1 (en) 2019-09-25
US10189818B2 (en) 2019-01-29
HK1254207B (en) 2020-05-22
WO2017100071A1 (en) 2017-06-15
CN108349948A (zh) 2018-07-31
AU2016367041B2 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
CO2017006962A2 (es) Derivados de 2-anilinopirimidina sustituida como moudladores de egfr
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
MX2017006224A (es) Derivados heterociclicos y usos de los mismos.
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
MX2017000450A (es) Compuestos terapeuticos inhibidores.
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
BR112016021012A2 (pt) composições farmacêuticas de compostos terapeuticamente ativos.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
AR103680A1 (es) Inhibidores selectivos de bace1
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
LT3436074T (lt) Tiazolido junginiai, skirti virusinių infekcijų gydymui
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
MX2019002369A (es) Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX390530B (es) Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos.
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
HUE053725T2 (hu) Aminotiolészter vegyületek vagy azok gyógyászatilag elfogadható sói, rák kezelésében történõ alkalmazásra